{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:30Z","timestamp":1792190490020,"version":"4.4.0"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, was effective and well tolerated at a dose of 6 mg once daily through 1\u2009year (52\u2009weeks) in patients with moderate to severe plaque psoriasis in the phase 3 POETYK PSO\u20101 and POETYK PSO\u20104 trials. Patients completing PSO\u20101 or PSO\u20104 could enter the ongoing POETYK long\u2010term extension trial and receive open\u2010label deucravacitinib. Safety and efficacy were evaluated through 3\u2009years (148\u2009weeks; data cutoff date: June 15, 2022) in Japanese patients in these trials. Safety was assessed via adverse events (AEs). Efficacy endpoints, including \u226575% reduction from baseline in the Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment (sPGA) score of 0\/1 (clear\/almost clear), were evaluated in patients receiving continuous deucravacitinib treatment from baseline in PSO\u20101 and PSO\u20104 and in PSO\u20101 patients crossing over from placebo to deucravacitinib at week 16. At data cutoff, 125 patients had received at least one deucravacitinib dose; 86.4% had &gt;24 months and 27.2% had &gt;36 months of total deucravacitinib exposure. Exposure\u2010adjusted incidence rates per 100 person\u2010years for AEs were: any AEs, 188.5; discontinuations attributable to AEs, 3.2; serious AEs, 7.4; serious infections, 1.3; herpes zoster events, 1.6; major adverse cardiovascular events, 0.6; venous thromboembolic events, 0; and malignancies, 1.0. Clinical responses (as observed) were maintained in PSO\u20101 patients receiving continuous deucravacitinib treatment from baseline (PASI 75: year 1, 88.9%; year 3, 87.5%; sPGA 0\/1: year 1, 74.1%; year 3, 66.7%). Year 1 response rates were also maintained through year 3 in PSO\u20104 patients and in PSO\u20101 placebo crossovers. Response rates were also consistent using modified nonresponder imputation and treatment failure rules data imputation methodologies. These findings support the consistent safety profile and durable efficacy of deucravacitinib through 3\u2009years in Japanese patients with psoriasis.<\/jats:p>\n                  <jats:p>ClinicalTrials.gov: NCT03624127; NCT03924427; NCT04036435.<\/jats:p>","DOI":"10.1111\/1346-8138.17685","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T08:12:34Z","timestamp":1741680754000},"page":"761-772","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Deucravacitinib in plaque psoriasis: Safety and efficacy through 3\u2009years in Japanese patients in the phase 3\n                    <scp>POETYK PSO<\/scp>\n                    \u20101,\n                    <scp>PSO<\/scp>\n                    \u20104, and\n                    <scp>LTE<\/scp>\n                    trials"],"prefix":"10.1111","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"first","affiliation":[{"name":"Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Fukuoka University Faculty of Medicine  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[{"name":"Teikyo University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-1259","authenticated-orcid":false,"given":"Yukari","family":"Okubo","sequence":"additional","affiliation":[{"name":"Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5722-854X","authenticated-orcid":false,"given":"Katsuyoshi","family":"Habiro","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuki","family":"Tsuritani","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Hoyt","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata M.","family":"Kisa","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7845-6698","authenticated-orcid":false,"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[{"name":"Jichi Medical University  Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17038"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0205-2"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16543"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16746"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13466"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_2_9_11_1","volume-title":"Sotyktu [package insert]","year":"2022"},{"key":"e_1_2_9_12_1","volume-title":"Sotyktu [package insert]","year":"2022"},{"key":"e_1_2_9_13_1","volume-title":"Sotyktu [product monograph]","year":"2022"},{"key":"e_1_2_9_14_1","volume-title":"Sotyktu [product information]","year":"2022"},{"key":"e_1_2_9_15_1","volume-title":"Sotyktu [European summary of product characteristics]","year":"2023"},{"key":"e_1_2_9_16_1","volume-title":"Sotyktu [package insert]","year":"2023"},{"key":"e_1_2_9_17_1","volume-title":"Sotyktu [package insert]","year":"2023"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16740"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17074"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae014"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4688"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"e_1_2_9_26_1","first-page":"734","article-title":"Methods for imputing missing efficacy data in clinical trials of biologic psoriasis therapies: implications for interpretations of trial results","volume":"16","author":"Langley RGB","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20595"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1782817"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216761"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.10.007"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae406"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20936059"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.017"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.996662"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000464"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac010"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15803"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17685","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.17685","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:39:25Z","timestamp":1772991565000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/1346-8138.17685"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17685","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"2024-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}